US20160207890A1 - Ethynyl derivatives - Google Patents
Ethynyl derivatives Download PDFInfo
- Publication number
- US20160207890A1 US20160207890A1 US15/081,573 US201615081573A US2016207890A1 US 20160207890 A1 US20160207890 A1 US 20160207890A1 US 201615081573 A US201615081573 A US 201615081573A US 2016207890 A1 US2016207890 A1 US 2016207890A1
- Authority
- US
- United States
- Prior art keywords
- dione
- phenyl
- phenylethynyl
- chloro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C(N2C(=O)C=CN([2*])C2=O)[Y]=CC(C#C[3*])=C1 Chemical compound [1*]C1=C(N2C(=O)C=CN([2*])C2=O)[Y]=CC(C#C[3*])=C1 0.000 description 32
- DHYVTLRGRODXJO-UHFFFAOYSA-N CN1N=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O Chemical compound CN1N=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O DHYVTLRGRODXJO-UHFFFAOYSA-N 0.000 description 4
- QLEGIGNLNGOPFM-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=C1C=CC=C2 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=C1C=CC=C2 QLEGIGNLNGOPFM-UHFFFAOYSA-N 0.000 description 3
- IEOSADZEDRCOTO-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=C2F)C(=O)C2=NN(C)C=C21 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=C2F)C(=O)C2=NN(C)C=C21 IEOSADZEDRCOTO-UHFFFAOYSA-N 0.000 description 3
- ITYCADPBUHMMBM-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CC=C2 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CC=C2 ITYCADPBUHMMBM-UHFFFAOYSA-N 0.000 description 3
- DRQORXLGWDMUPR-UHFFFAOYSA-N CC1=CC2=C(C=C1)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C Chemical compound CC1=CC2=C(C=C1)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C DRQORXLGWDMUPR-UHFFFAOYSA-N 0.000 description 3
- QBTLEYDLXVNKID-UHFFFAOYSA-N CC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=N1)C2=O Chemical compound CC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=N1)C2=O QBTLEYDLXVNKID-UHFFFAOYSA-N 0.000 description 3
- JQYFSDBWDZVIDM-UHFFFAOYSA-N CC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O Chemical compound CC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O JQYFSDBWDZVIDM-UHFFFAOYSA-N 0.000 description 3
- NPHINVYPKVTFEM-UHFFFAOYSA-N CC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CN=CC=C3)C=C1F)C2=O Chemical compound CC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CN=CC=C3)C=C1F)C2=O NPHINVYPKVTFEM-UHFFFAOYSA-N 0.000 description 3
- KUNWSKGTYFFAGB-UHFFFAOYSA-N CC1=CSC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O Chemical compound CC1=CSC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O KUNWSKGTYFFAGB-UHFFFAOYSA-N 0.000 description 3
- CRUXMMQUQLUWDJ-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C(F)=C(F)C=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C(F)=C(F)C=C2 CRUXMMQUQLUWDJ-UHFFFAOYSA-N 0.000 description 3
- BBSWUSZGNLILJJ-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 BBSWUSZGNLILJJ-UHFFFAOYSA-N 0.000 description 3
- DKNFKGLGSBIODB-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=C(N1CCOCC1)S2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=C(N1CCOCC1)S2 DKNFKGLGSBIODB-UHFFFAOYSA-N 0.000 description 3
- SDWOIAFUJHLTEQ-UHFFFAOYSA-N COC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O Chemical compound COC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O SDWOIAFUJHLTEQ-UHFFFAOYSA-N 0.000 description 3
- FGNNIVUEVKRYKM-UHFFFAOYSA-N CC(C)C1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O Chemical compound CC(C)C1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O FGNNIVUEVKRYKM-UHFFFAOYSA-N 0.000 description 2
- KXOHNGYEMZLVFJ-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(C(F)(F)F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C=CC=C2 Chemical compound CC(C)N1C(=O)N(C2=C(C(F)(F)F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C=CC=C2 KXOHNGYEMZLVFJ-UHFFFAOYSA-N 0.000 description 2
- QVIAQHCWUCZUAC-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 QVIAQHCWUCZUAC-UHFFFAOYSA-N 0.000 description 2
- IFJNXSCYWXJPSK-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CC=N2 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CC=N2 IFJNXSCYWXJPSK-UHFFFAOYSA-N 0.000 description 2
- SIVGUUNOMAWSCW-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=NN(C)C=C21 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=NN(C)C=C21 SIVGUUNOMAWSCW-UHFFFAOYSA-N 0.000 description 2
- XXISEHFXMRPIEF-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=C2)C(=O)C2=C1N=CC=N2 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=C2)C(=O)C2=C1N=CC=N2 XXISEHFXMRPIEF-UHFFFAOYSA-N 0.000 description 2
- RKLHULFQZMWCAJ-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=C2F)C(=O)C2=C1C=CC=C2 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=C2F)C(=O)C2=C1C=CC=C2 RKLHULFQZMWCAJ-UHFFFAOYSA-N 0.000 description 2
- ZRXDYGWUBMPXRA-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=N2)C(=O)C2=NN(C)C=C21 Chemical compound CC(C)N1C(=O)N(C2=C(Cl)C=C(C#CC3=CN=CC=C3)C=N2)C(=O)C2=NN(C)C=C21 ZRXDYGWUBMPXRA-UHFFFAOYSA-N 0.000 description 2
- KYQSCKLDBXKEAK-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C=NN2C Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C=NN2C KYQSCKLDBXKEAK-UHFFFAOYSA-N 0.000 description 2
- LEARBUPBWCKPLJ-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CC=N2 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CC=N2 LEARBUPBWCKPLJ-UHFFFAOYSA-N 0.000 description 2
- OBZLWCJHONWCLS-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=CNN=C21 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=CNN=C21 OBZLWCJHONWCLS-UHFFFAOYSA-N 0.000 description 2
- OGGREJJJLSDMSD-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=NN(C)C=C21 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=NN(C)C=C21 OGGREJJJLSDMSD-UHFFFAOYSA-N 0.000 description 2
- FXUOEULHWMPBOQ-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=NSN=C21 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=NSN=C21 FXUOEULHWMPBOQ-UHFFFAOYSA-N 0.000 description 2
- WVIJILXYSRYBOH-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=NN(C)C=C21 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=NN(C)C=C21 WVIJILXYSRYBOH-UHFFFAOYSA-N 0.000 description 2
- VGOTUHXUGHTBEB-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CN=CC=C3)C=C2F)C(=O)C2=NN(C)C=C21 Chemical compound CC(C)N1C(=O)N(C2=C(F)C=C(C#CC3=CN=CC=C3)C=C2F)C(=O)C2=NN(C)C=C21 VGOTUHXUGHTBEB-UHFFFAOYSA-N 0.000 description 2
- DBFOULRJKSBUGQ-UHFFFAOYSA-N CC(C)N1C(=O)N(C2=NC=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 Chemical compound CC(C)N1C(=O)N(C2=NC=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 DBFOULRJKSBUGQ-UHFFFAOYSA-N 0.000 description 2
- BYQALYAQTODCTI-UHFFFAOYSA-N CC1=CC2=C(C=C1)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C(=O)N2C Chemical compound CC1=CC2=C(C=C1)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C(=O)N2C BYQALYAQTODCTI-UHFFFAOYSA-N 0.000 description 2
- ZPDARFHWQDNJBQ-UHFFFAOYSA-N CC1=CC=CC2=C1C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C(=O)N2C Chemical compound CC1=CC=CC2=C1C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C(=O)N2C ZPDARFHWQDNJBQ-UHFFFAOYSA-N 0.000 description 2
- KXAHKQFCQQBJTI-UHFFFAOYSA-N CC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O Chemical compound CC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O KXAHKQFCQQBJTI-UHFFFAOYSA-N 0.000 description 2
- NPONPBWCZZZIOS-UHFFFAOYSA-N CC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CN=CC=C3)C=C1F)C2=O Chemical compound CC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CN=CC=C3)C=C1F)C2=O NPONPBWCZZZIOS-UHFFFAOYSA-N 0.000 description 2
- HGIYCZRMHAVMGV-UHFFFAOYSA-N CC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=N1)C2=O Chemical compound CC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=N1)C2=O HGIYCZRMHAVMGV-UHFFFAOYSA-N 0.000 description 2
- QMNJGLJZTAVESW-UHFFFAOYSA-N CC1=CC=NC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O Chemical compound CC1=CC=NC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O QMNJGLJZTAVESW-UHFFFAOYSA-N 0.000 description 2
- DHTWJHLALCXHPQ-UHFFFAOYSA-N CC1=CSC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O Chemical compound CC1=CSC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O DHTWJHLALCXHPQ-UHFFFAOYSA-N 0.000 description 2
- ITPNKBNUEGONAA-UHFFFAOYSA-N CC1=CSC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CN=CC=C3)C=C1F)C2=O Chemical compound CC1=CSC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CN=CC=C3)C=C1F)C2=O ITPNKBNUEGONAA-UHFFFAOYSA-N 0.000 description 2
- KPJNQPREOODLLV-UHFFFAOYSA-N CCC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O Chemical compound CCC1=CC=CC2=C1N(C)C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C2=O KPJNQPREOODLLV-UHFFFAOYSA-N 0.000 description 2
- KDYSXFZUHADIMX-UHFFFAOYSA-N CCN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 Chemical compound CCN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 KDYSXFZUHADIMX-UHFFFAOYSA-N 0.000 description 2
- OAWDPGNXSKNYSO-UHFFFAOYSA-N CN1C(=O)N(C2=C(C(F)(F)F)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=C1C=CC=C2 Chemical compound CN1C(=O)N(C2=C(C(F)(F)F)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=C1C=CC=C2 OAWDPGNXSKNYSO-UHFFFAOYSA-N 0.000 description 2
- PLRNQXWIEVVJPJ-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C(Cl)=CC=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C(Cl)=CC=C2 PLRNQXWIEVVJPJ-UHFFFAOYSA-N 0.000 description 2
- HRYBUMUDQNINCW-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=C(Cl)C=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=C(Cl)C=C2 HRYBUMUDQNINCW-UHFFFAOYSA-N 0.000 description 2
- MWZNYOLHICBZFX-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC(F)=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC(F)=C2 MWZNYOLHICBZFX-UHFFFAOYSA-N 0.000 description 2
- YIZSQGFIXCTNBT-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=N2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=N2 YIZSQGFIXCTNBT-UHFFFAOYSA-N 0.000 description 2
- QKZVCECVTSICEI-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CN=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CN=C2 QKZVCECVTSICEI-UHFFFAOYSA-N 0.000 description 2
- CZQIDHOPIUYAGB-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CC=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CC=C2 CZQIDHOPIUYAGB-UHFFFAOYSA-N 0.000 description 2
- LUSZSFOVIVRWMX-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CC=N2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CC=N2 LUSZSFOVIVRWMX-UHFFFAOYSA-N 0.000 description 2
- ZPVQDMYDGXHNPO-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CN=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CN=C2 ZPVQDMYDGXHNPO-UHFFFAOYSA-N 0.000 description 2
- SXBKMHPXNKQHFN-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CS2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1N=CS2 SXBKMHPXNKQHFN-UHFFFAOYSA-N 0.000 description 2
- CAJAKRRNZAIKJX-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1SC=N2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1SC=N2 CAJAKRRNZAIKJX-UHFFFAOYSA-N 0.000 description 2
- HAEAIGOGBKJULN-UHFFFAOYSA-N CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=C1C=CC=C2 Chemical compound CN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=N2)C(=O)C2=C1C=CC=C2 HAEAIGOGBKJULN-UHFFFAOYSA-N 0.000 description 2
- OOWNPNOQPWRCKQ-UHFFFAOYSA-N CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C(Cl)=CC=N2 Chemical compound CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C(Cl)=CC=N2 OOWNPNOQPWRCKQ-UHFFFAOYSA-N 0.000 description 2
- ACGDPKODSMFODO-UHFFFAOYSA-N CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C(OCC(F)F)=CC=C2 Chemical compound CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C(OCC(F)F)=CC=C2 ACGDPKODSMFODO-UHFFFAOYSA-N 0.000 description 2
- VSIVOIDZOYRCIB-UHFFFAOYSA-N CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C=CC=C2 Chemical compound CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1C=CC=C2 VSIVOIDZOYRCIB-UHFFFAOYSA-N 0.000 description 2
- KAJPRYJCXQRTQE-UHFFFAOYSA-N CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CC=C2 Chemical compound CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CC=C2 KAJPRYJCXQRTQE-UHFFFAOYSA-N 0.000 description 2
- PRHFFXZKPWMSEG-UHFFFAOYSA-N CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CS2 Chemical compound CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=C1N=CS2 PRHFFXZKPWMSEG-UHFFFAOYSA-N 0.000 description 2
- PVHUDCFEPAPXQB-UHFFFAOYSA-N CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=NSN=C21 Chemical compound CN1C(=O)N(C2=C(F)C=C(C#CC3=CC=CC=C3)C=C2F)C(=O)C2=NSN=C21 PVHUDCFEPAPXQB-UHFFFAOYSA-N 0.000 description 2
- OTIYMSXTQNKCFH-UHFFFAOYSA-N CN1C=C2C(=N1)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C Chemical compound CN1C=C2C(=N1)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C OTIYMSXTQNKCFH-UHFFFAOYSA-N 0.000 description 2
- VWOKYKJAEIIEJY-UHFFFAOYSA-N CN1C=C2C(=O)N(C3=C(F)C=C(C#CC4=CC=CC=C4)C=C3F)C(=O)N(C)C2=N1 Chemical compound CN1C=C2C(=O)N(C3=C(F)C=C(C#CC4=CC=CC=C4)C=C3F)C(=O)N(C)C2=N1 VWOKYKJAEIIEJY-UHFFFAOYSA-N 0.000 description 2
- MYNOYCZAIVKMAI-UHFFFAOYSA-N CN1C=NC2=C1C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C(=O)N2C Chemical compound CN1C=NC2=C1C(=O)N(C1=C(Cl)C=C(C#CC3=CC=CC=C3)C=C1)C(=O)N2C MYNOYCZAIVKMAI-UHFFFAOYSA-N 0.000 description 2
- QXBBODBEGWJWFX-UHFFFAOYSA-N CN1C=NC2=C1C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C Chemical compound CN1C=NC2=C1C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C QXBBODBEGWJWFX-UHFFFAOYSA-N 0.000 description 2
- CIIZISUUSIUNFS-UHFFFAOYSA-N CN1N=CC2=C1C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C Chemical compound CN1N=CC2=C1C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C(=O)N2C CIIZISUUSIUNFS-UHFFFAOYSA-N 0.000 description 2
- DAKDRHYJYCFOPC-UHFFFAOYSA-N COC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O Chemical compound COC1=CC=CC2=C1N(C)C(=O)N(C1=C(F)C=C(C#CC3=CC=CC=C3)C=C1F)C2=O DAKDRHYJYCFOPC-UHFFFAOYSA-N 0.000 description 2
- ZDANCVQWMJDAOJ-UHFFFAOYSA-N COCCN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 Chemical compound COCCN1C(=O)N(C2=C(Cl)C=C(C#CC3=CC=CC=C3)C=C2)C(=O)C2=C1C=CC=C2 ZDANCVQWMJDAOJ-UHFFFAOYSA-N 0.000 description 2
- SHTBCZMVAJLAAC-UHFFFAOYSA-N O=C1C2=C(C=CC=C2)N(C2CCC2)C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 Chemical compound O=C1C2=C(C=CC=C2)N(C2CCC2)C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 SHTBCZMVAJLAAC-UHFFFAOYSA-N 0.000 description 2
- UADWGPXPESRORL-UHFFFAOYSA-N O=C1C2=C(C=CC=C2)N(C2COC2)C(=O)N1C1=C(Cl)C=C(C#CC2=CN=CC=C2)C=C1F Chemical compound O=C1C2=C(C=CC=C2)N(C2COC2)C(=O)N1C1=C(Cl)C=C(C#CC2=CN=CC=C2)C=C1F UADWGPXPESRORL-UHFFFAOYSA-N 0.000 description 2
- UURNPOACTUOVAM-UHFFFAOYSA-N O=C1C2=C(C=CC=C2)N(C2COC2)C(=O)N1C1=C(F)C=C(C#CC2=CC=CC=C2)C=C1F Chemical compound O=C1C2=C(C=CC=C2)N(C2COC2)C(=O)N1C1=C(F)C=C(C#CC2=CC=CC=C2)C=C1F UURNPOACTUOVAM-UHFFFAOYSA-N 0.000 description 2
- TWTNOSXTNOREHM-UHFFFAOYSA-N O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 Chemical compound O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 TWTNOSXTNOREHM-UHFFFAOYSA-N 0.000 description 2
- YGIZBNHCAYOICQ-UHFFFAOYSA-N O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=N1 Chemical compound O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=N1 YGIZBNHCAYOICQ-UHFFFAOYSA-N 0.000 description 2
- ZINNBCHRLHPMLY-UHFFFAOYSA-N O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(F)C=C(C#CC2=CC=CC=C2)C=C1F Chemical compound O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(F)C=C(C#CC2=CC=CC=C2)C=C1F ZINNBCHRLHPMLY-UHFFFAOYSA-N 0.000 description 2
- JIZKAOYGASFHJF-UHFFFAOYSA-N O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(F)C=C(C#CC2=CN=CC=C2)C=C1F Chemical compound O=C1C2=C3/C(=C\C=C/2)CCN3C(=O)N1C1=C(F)C=C(C#CC2=CN=CC=C2)C=C1F JIZKAOYGASFHJF-UHFFFAOYSA-N 0.000 description 2
- CQBPYELACXTOTO-UHFFFAOYSA-N O=C1CC2=C(C=CC=N2)C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 Chemical compound O=C1CC2=C(C=CC=N2)C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 CQBPYELACXTOTO-UHFFFAOYSA-N 0.000 description 2
- FQAJVWUUXKPRGU-UHFFFAOYSA-N O=C1CC2=C(C=NC=N2)C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 Chemical compound O=C1CC2=C(C=NC=N2)C(=O)N1C1=C(Cl)C=C(C#CC2=CC=CC=C2)C=C1 FQAJVWUUXKPRGU-UHFFFAOYSA-N 0.000 description 2
- OCTFWXVEBHBXIV-UHFFFAOYSA-N O=C1CC2=C(SC=N2)C(=O)N1C1=C(F)C=C(C#CC2=CC=CC=C2)C=C1F Chemical compound O=C1CC2=C(SC=N2)C(=O)N1C1=C(F)C=C(C#CC2=CC=CC=C2)C=C1F OCTFWXVEBHBXIV-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N C1=CC=CC=C1.N Chemical compound C1=CC=CC=C1.N UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to compounds of formula I
- the compounds of general formula I are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4).
- Metabotropic glutamate receptor 4 is a protein that in humans is encoded by the GRM4 gene.
- GRM6 GRM7 and GRM8 it belongs to group III of the Metabotropic glutamate receptor family, and is negatively coupled to adenylate cyclase via activation of the G ⁇ i/o protein. It is expressed primarily on presynaptic terminals, functioning as an autoreceptor or heteroceptor and its activation leads to decreases in transmitter release from presynaptic terminals.
- mGluR4 is currently receiving much attention based primarily upon its unique distribution and the recent evidence that activation of this receptor plays key modulatory role in many CNS and non-CNS pathways (Celanire S, Campo B, Expert Opinion in Drug Discovery, 2012)
- mGluR4 PAM is emerging as a promising target for the treatment of motor (and non motor) symptoms as well as a disease-modifying agent in Parkinson's disease through a non-dopaminergic approach.
- Parkinson's disease is a progressive neurodegenerative disease that results in the loss of dopaminergic neurons in the substantia nigra (SN).
- SN substantia nigra
- Parkinson's disease is a progressive neurodegenerative disease that results in the loss of dopaminergic neurons in the substantia nigra (SN).
- One consequence of the depletion of dopamine in this disease is a series of movement disorders, including bradykinesia, akinesia, tremor, gait disorders and problems with balance.
- These motor disturbances form the hallmark of PD, although there are many other non-motor symptoms that are associated with the disease.
- PD symptoms are effectively treated by dopamine replacement or augmentation, with the use of dopamine D2 receptor agonists, levodopa or monoamine oxidase B inhibitors.
- dopamine D2 receptor agonists e.
- levodopa or monoamine oxidase B inhibitors oxidase B
- mGluR4 metabotropic glutamate receptor 4
- group III mGluRs A member of the group III mGluRs, mGluR4 is predominantly a presynaptic glutamate receptor that is expressed in several key locations in the basal ganglia circuits that control movement.
- Activation of mGluR4 with group III-preferring agonists decreases inhibitory and excitatory post synaptic potentials, presumably by decreasing the release of GABA and glutamate respectively.
- Orthosteric mGluR4 agonist L-AP4 has demonstrated neuroprotective effects in a 6-OHDA rodent model of PD and first positive allosteric modulator ( ⁇ )-PHCCC reduced nigrostriatal degeneration in mice treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).
- MPTP 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine
- Anxiety disorders are among the most prevalent psychiatric disorders in the world, and are co-morbid with Parkinson's disease (Prediger R, et al. Neuropharmacology 2012; 62:115-24). Excessive glutamatergic neurotransmission is one important feature of anxiety pathophysiology. Based on presynaptic localization of mGluR4 in brain areas involved in anxiety and mood disorders, and dampening excessive brain excitability, the mGluR4 activators may represent a new generation of anxiolytic therapeutics ( Eur. J. Pharmacol., 498(1-3), 153-6, 2004).
- ADX88178 was active in two preclinical rodent models of anxiety: the marble burying test in mice and EPM in mice and rats. ADX88178 also displayed an anxiolytic-like profile in the rat EPM test after oral dosing.
- mGluR4 modulators were also shown to exert anti-depressive actions ( Neuropharmacology, 46(2), 151-9, 2004).
- mGluR4 were also shown to be involved in glucagon secretion inhibition ( Diabetes, 53(4), 998-1006, 2004). Therefore, orthosteric or positive allosteric modulators of mGluR4 have potential for the treatment of type 2 diabetes through its hypoglycemic effect.
- mGluR4 was shown to be expressed in prostate cancer cell-line ( Anticancer Res. 29(1), 371-7, 2009) or colorectal carcinoma ( Cli. Cancer Research, 11(9)3288-95, 2005). mGluR4 modulators may therefore have also potential role for the treatment of cancers.
- MgluR4 PAM's can be expected for the treatment of emesis, obsessive compulsive disorder and autism.
- Compounds of formula I are distinguished by having valuable therapeutic properties. They can be used in the treatment or prevention of disorders, relating to allosteric modulators for the mGluR4 receptor.
- the most preferred indications for compounds which are allosteric modulators for the mGluR4 receptor are Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
- the present invention relates to compounds of formula I and to their pharmaceutically acceptable salts, to these compounds as pharmaceutically active substances, to the processes for their production as well as to the use in the treatment or prevention of disorders, relating to allosteric modulators for the mGluR4 receptor, such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2 and to pharmaceutical compositions containing the compounds of formula I.
- allosteric modulators for the mGluR4 receptor such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2 and to pharmaceutical compositions containing the compounds of formula I.
- a further object of the present invention is a method for the treatment or prophylaxis of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2, which method comprises administering an effective amount of a compound of formula I to a mammal in need.
- the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers.
- FIG. 1 is an illustration of the experimental outline for the mGlu4 PAM Ca2+ mobilization screening assay and the determination of EC 50 and % Emax values.
- lower alkyl denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like.
- Preferred alkyl groups are groups with 1-4 carbon atoms.
- lower alkoxy denotes a lower alkyl group as defined above, which is linked with an O atom.
- cycloalkyl denotes a saturated ring containing from 3 to 7 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl or cycloheptenyl.
- heterocycloalkyl denoted a cycloalkyl ring as defined above, wherein at least one carbon atom is replaced by O, N, or S, for example tetrahydrofuranyl, morpholinyl piperidinyl or oxetanyl.
- halogen denotes chlorine, iodine, fluorine and bromine.
- lower alkyl substituted by halogen denotes a lower alkyl group as defined above, wherein at least one hydrogen atom is replaced by a halogen atom, for example the following groups: CF 3 , CHF 2 , CH 2 F, CH 2 CF 3 , CH 2 CHF 2 , CH 2 CH 2 F, CH 2 CH 2 CF 3 , CH 2 CH 2 CH 2 CF 3 , CH 2 CH 2 Cl, CH 2 CF 2 CF 3 , CH 2 CF 2 CHF 2 , CF 2 CHFCF 3 , C(CH 3 ) 2 CF 3 , CH(CH 3 )CF 3 or CH(CH 2 F)CH 2 F.
- the preferred “lower alkyl substituted by halogen” group is CF 3 .
- lower alkoxy substituted by halogen denotes an alkoxy group as defined above, wherein at least one hydrogen atom is replaced by halogen.
- a preferred group is OCH 2 CHF 2 .
- five or six membered saturated heterocyclic group which may contain an additional oxygen, NH or N-lower alkyl group denotes a piperidine group, a piperazine group or a morpholine group.
- lower alkoxyalkyl denotes an alkyl group as defined above and which is linked with an alkoxy group.
- N atom is a pyridine group, wherein the N atom may be in different positions, or means the group
- pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
- One embodiment of the invention is further compounds of formula IB,
- One embodiment of the invention is compounds of formula ID,
- the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art.
- the reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
- An ethynyl-phenyl, ethynyl-pyridyl substituted pyrimidinedione compound of formula I can be obtained for example by reacting an appropriately substituted aniline or aminopyridine 1 with an appropriate aromatic or heteroaromatic orthoaminoester 2 with phosgene or a phosgene equivalent such as triphosgene or carbonyldiimidazole (CDI) in presence or absence of a base such as triethylamine in a solvent such as toluene or dioxane to form the corresponding pyrimidine dione of formula 3.
- phosgene or a phosgene equivalent such as triphosgene or carbonyldiimidazole (CDI)
- sequence of steps used to synthesize the compounds of formula I can also be modified in certain cases, for example by first running the Sonogashira coupling with an appropriately substituted bromo or iodo aniline or aminopyridine 1 with an appropriately substituted arylacetylene 4 to yield the corresponding ethynyl compounds 5.
- Reacting 5 with an appropriate aromatic or heteroaromatic orthoaminoester 2 with phosgene or a phosgene equivalent such as triphosgene or carbonyldiimidazole (CDI) in presence or absence of a base such as triethylamine in a solvent such as toluene or dioxane yield the desired ethynyl compounds of general formula I (scheme 2).
- phosgene or a phosgene equivalent such as triphosgene or carbonyldiimidazole (CDI)
- a base such as triethylamine
- a solvent such as toluene or dioxane
- Cells were cultured according to standard protocols (Freshney, 2000) in Dulbecco's Modified Eagle Medium with high glucose supplemented with 1 mM glutamine, 10% (vol/vol) heat-inactivated bovine calf serum, Penicillin/Streptomycin, 50 ⁇ g/ml hygromycin and 15 ⁇ g/ml blasticidin (all cell culture reagents and antibiotics from Invitrogen, Basel, Switzerland). About 24 hrs before an experiment, 5 ⁇ 10 4 cells/well were seeded in poly-D-lysine coated, black/clear-bottomed 96-well plates.
- the cells were loaded with 2.5 ⁇ M Fluo-4AM in loading buffer (1 ⁇ HBSS, 20 mM HEPES) for 1 hr at 37° C. and washed five times with loading buffer.
- the cells were transferred into a Functional Drug Screening System 7000 (Hamamatsu, Paris, France), and 11 half logarithmic serial dilutions of test compound at 37° C. were added and the cells were incubated for 10-30 min. with on-line recording of fluorescence.
- L-AP4 (2S)-2-amino-4-phosphonobutanoic acid
- EC 20 of L-AP4 was determined immediately ahead of each experiment by recording of a full dose-response curve of L-AP4. Responses were measured as peak increase in fluorescence minus basal (i.e. fluorescence without addition of L-AP4), normalized to the maximal stimulatory effect obtained with saturating concentrations of L-AP4.
- Graphs were plotted with the % maximal stimulatory using XLfit, a curve fitting program that iteratively plots the data using Levenburg Marquardt algorithm.
- the EC 50 drug concentration at which 50% of the maximal receptor activation was achieved
- the Hill coefficient as well as the maximal response in % of the maximal stimulatory effect obtained with saturating concentrations of L-AP4 were calculated (see FIG. 1 ).
- Positive signals obtained during the pre-incubation with the PAM test compounds i.e. before application of an EC 20 concentration of L-AP4 were indicative of an agonistic activity, the absence of such signals were demonstrating the lack of agonistic activities.
- a depression of the signal observed after addition of the EC 20 concentration of L-AP4 was indicative of an inhibitory activity of the test compound.
- FIG. 1 Illustration of the experimental outline for mGlu4 PAM Ca2+ mobilization screening assay and the determination of EC 50 and % Emax values.
- the compounds of formula (I) and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations.
- the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
- the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
- the compounds of formula (I) and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
- Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatin capsules.
- Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatin capsules.
- Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
- Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula (I), but as a rule are not necessary.
- Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
- the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- medicaments containing a compound of formula (I) or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
- the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
- the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/kg/day being preferred for all of the indications described.
- Methyl 2-aminobenzoate (100 mg, 0.66 mmol) was dissolved in dioxane (1.5 ml) and 2-chloro-4-iodo-1-isocyanato-benzene (Example 1, step 1) (203 mg, 0.73 mmol, 1.1 equiv.) and triethylamine (250 ⁇ l, 1.79 mmol, 2.7 equiv.) were added at room temperature. The mixture was stirred for 16 hours at 85° C.
- Triethylamine (157 mg, 217 ⁇ l, 1.56 mmol, 4 equiv.), triphenylphosphine (6 mg, 23.4 ⁇ mol, 0.06 equiv.) and copper(I)iodide (2 mg, 7.8 ⁇ mol, 0.02 equiv.) were added and the mixture was stirred for 2 hours at 50° C.
- the reaction mixture was cooled and extracted with saturated NaHCO 3 solution and two times with ethyl acetate. The organic layers were washed three times with water, dried over sodium sulfate and evaporated to dryness.
- Step 4 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1-methyl-quinazoline-2,4-dione
- Step 3 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1,8-dimethyl-quinazoline-2,4-dione
- Step 3 8-Chloro-3-[2-chloro-4-(2-phenylethynyl)phenyl]-1-methyl-quinazoline-2,4-dione
- Example 4 The title compound was obtained as a dark brown waxy solid, using chemistry similar to that described in Example 1, step 1 from 2-chloro-4-(2-phenylethynyl)aniline (Example 4, step 1).
- Step 3 7-Chloro-3-[2-chloro-4-(2-phenylethynyl)phenyl]-1H-quinazoline-2,4-dione
- Step 3 7-Chloro-3-[2-chloro-4-(2-phenylethynyl)phenyl]-1-methyl-quinazoline-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1,7-dimethyl-quinazoline-2,4-dione
- Step 1 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-8-ethyl-1H-quinazoline-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-8-ethyl-1-methyl-quinazoline-2,4-dione
- Step 1 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1H-pyrido[3,2-d]pyrimidine-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1-methyl-pyrido[3,2-d]pyrimidine-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1H-pyrido[4,3-d]pyrimidine-2,4-dione
- Step 3 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1-methyl-pyrido[4,3-d]pyrimidine-2,4-dione
- Step 1 Ethyl 5-[(2-chloro-4-iodo-phenyl)carbamoylamino]-3-methyl-imidazole-4-carboxylate
- Step 4 1-[2-Chloro-4-(2-phenylethynyl)phenyl]-3,7-dimethyl-purine-2,6-dione
- Step 1 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-6-fluoro-1H-quinazoline-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-6-fluoro-1-methyl-quinazoline-2,4-dione
- Step 1 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-7,8-difluoro-1H-quinazoline-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-7,8-difluoro-1-methyl-quinazoline-2,4-dione
- Step 1 3-(2-Chloro-4-phenylethynyl-phenyl)-7-methyl-1H-thieno[3,2-d]pyrimidine-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1,7-dimethyl-thieno[3,2-d]pyrimidine-2,4-dione
- Step 2 3-(2-Chloro-4-iodo-phenyl)-1-isopropyl-pteridine-2,4-dione
- Step 3 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1-isopropyl-pteridine-2,4-dione
- Step 3 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1-methyl-quinazoline-2,4-dione
- Step 3 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1,8-dimethyl-quinazoline-2,4-dione
- Step 2 3-(2,6-Difluoro-4-phenylethynyl-phenyl)-1H-pyrido[23-d]pyrimidine-2,4-dione
- Step 3 3-(2,6-Difluoro-4-phenylethynyl-phenyl)-1-methyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione
- Step 1 3-(2,6-Difluoro-4-phenylethynyl-phenyl)-7-methyl-1H-quinazoline-2,4-dione
- Step 2 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1,7-dimethyl-quinazoline-2,4-dione
- Step 1 3-(2,6-Difluoro-4-phenylethynyl-phenyl)-7-methyl-1H-thieno[3,2-d]pyrimidine-2,4-dione
- Step 2 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1,7-dimethyl-thieno[3,2-d]pyrimidine-2,4-dione
- Step 2 3-(2,6-Difluoro-4-pyridin-3-ylethynyl-phenyl)-7-methyl-1H-thieno[3,2-d]pyrimidine-2,4-dione
- Step 3 3-[2,6-Difluoro-4-[2-(3-pyridyl)ethynyl]phenyl]-1,7-dimethyl-thieno[3,2d]pyrimidine-2,4-dione
- Step 1 Methyl 4-[[2,6-difluoro-4-(2-phenylethynyl)phenyl]carbamoylamino]-1-methyl-pyrazole-3-carboxylate
- 2,6-Difluoro-4-phenylethynyl-phenylamine (Example 25, step 1) (200 mg, 0.87 mmol) was dissolved in toluene (6.0 ml) and bis(trichloromethyl) carbonate (104 mg, 0.35 mmol, 0.4 equiv.) was added at room temperature. The mixture was stirred for 1 hour at 110° C. The mixture was cooled to room temperature and Et 3 N (440 mg, 0.61 ml, 4.36 mmol, 5 equiv.) and methyl 4-amino-1-methyl-1H-pyrazole-3-carboxylate (135 mg, 0.87 mmol, 1.0 equiv.) were added at room temperature.
- Et 3 N 440 mg, 0.61 ml, 4.36 mmol, 5 equiv.
- methyl 4-amino-1-methyl-1H-pyrazole-3-carboxylate (135 mg, 0.87 mmol, 1.0 equiv.
- Step 2 6-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-2-methyl-4H-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 3 6-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-2,4-dimethyl-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 1 6-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1-methyl-4H-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 2 6-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1, 4-dimethyl-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 1 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-8-methyl-H-pyrido[3, 2-d]pyrimidine-2,4-dione
- Step 2 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1,8-dimethyl-pyrido[3,2-d]pyrimidine-2,4-dione
- Step 1 6-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-4H-[1,2,5]thiadiazolo[3,4-d]pyrimidine-5,7-dione
- Step 2 6-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-4-methyl-[1,2,5]thiadiazolo[3,4-d]pyrimidine-5,7-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-1,5-dimethyl-quinazoline-2,4-dione
- Methyl 2-aminobenzoate (2 g, 13.2 mmol) was dissolved in dichloromethane (6.0 ml) and trifluoroacetic acid (2.0 ml, 26.5 mmol, 2.0 equiv.), acetone (2.91 ml, 39.7 mmol, 3 equiv.) and tetramethylammonium triacetoxyborohydride (5.22 g, 19.8 mmol, 1.5 equiv.) were added at room temperature. The mixture was stirred for 16 hour at room temperature. The reaction mixture was extracted with saturated NaHCO 3 solution and twice with dichloromethane. The organic layers were combined and evaporated to dryness.
- Step 3 3-[2-Chloro-6-fluoro-4-[2-(3-pyridyl)ethynyl]phenyl]-1-isopropyl-quinazoline-2,4-dione
- Step 1 3-[2-Chloro-6-fluoro-4-[2-(3-pyridyl)ethynyl]phenyl]-8-methyl-1H-quinazoline-2,4-dione
- Step 3 3-[3-Chloro-5-(2-phenylethynyl)-2-pyridyl]-1-methyl-quinazoline-2,4-dione
- Step 1 3-[3-Chloro-5-(2-phenylethynyl)-2-pyridyl]-8-methyl-1H-quinazoline-2,4-dione
- Step 3 3-[3-Chloro-5-(2-phenylethynyl)-2-pyridyl]-1,8-dimethyl-quinazoline-2,4-dione
- Step 2 3-[5-(2-Phenylethynyl)-3-(trifluoromethyl)-2-pyridyl]-1H-quinazoline-2,4-dione
- Step 2 1-Methyl-3-[5-(2-phenylethynyl)-3-(trifluoromethyl)-2-pyridyl]quinazoline-2,4-dione
- Step 2 3-[3-Fluoro-5-(2-phenylethynyl)-2-pyridyl]-8-methyl-1H-quinazoline-2,4-dione
- Step 3 3-[3-Fluoro-5-(2-phenylethynyl)-2-pyridyl]-1,8-dimethyl-quinazoline-2,4-dione
- Step 1 Methyl 4-[[2-chloro-4-(2-phenylethynyl)phenyl]carbamoylamino]-2-morpholino-thiazole-5-carboxylate
- Step 2 6-[2-Chloro-4-(2-phenylethynyl)phenyl]-2-morpholino-4H-thiazolo[4,5-d]pyrimidine-5,7-dione
- Step 3 6-[2-Chloro-4-(2-phenylethynyl)phenyl]-4-methyl-2-morpholino-thiazolo[4,5-d]pyrimidine-5,7-dione
- Step 1 6-(2-Chloro-4-phenylethynyl-phenyl)-4H-thiazolo[4,5-d]pyrimidine-5,7-dione
- Step 2 6-(2-Chloro-4-phenylethynyl-phenyl)-4-methyl-4H-thiazolo[4,5-d]pyrimidine-5,7-dione
- Step 1 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-8-isopropyl-1H-quinazoline-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-8-isopropyl-1-methyl-quinazoline-2,4-dione
- Step 1 3-(5-Bromo-2-pyridyl)-1-isopropyl-quinazoline-2,4-dione
- Step 2 6-[3-Fluoro-5-(2-phenylethynyl)-2-pyridyl]-4-isopropyl-2-methyl-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 2 6-[2,6-Difluoro-4-[2-(3-pyridyl)ethynyl]phenyl]-4-isopropyl-2 ethyl-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 1 6-(5-bromo-3-chloro-2-pyridyl)-4-isopropyl-2-methyl-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 2 6-[3-Chloro-5-[2-(3-pyridyl)ethynyl]-2-pyridyl]-4-isopropyl-2-methyl-pyrazolo[4,3-d]pyrimidine-5,7-dione
- Step 1 8-Chloro-3-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-1H-pyrido[3,2-d]pyrimidine-2,4-dione
- Step 2 8-Chloro-3-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-1-methyl-pyrido[3,2-d]pyrimidine-2,4-dione
- Step 1 Methyl 3-[[2,6-difluoro-4-(2-phenylethynyl)phenyl]carbamoylamino]-1-methyl-pyrazole-4-carboxylate
- Step 3 5-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-2,7-dimethyl-pyrazolo[3,4-d]pyrimidine-4,6-dione
- Step 1 Methyl 5-[[2,6-difluoro-4-(2-phenylethynyl)phenyl]carbamoylamino]-1-methyl-pyrazole-4-carboxylate
- Step 3 5-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1,7-dimethyl-pyrazolo[34-d]pyrimidine-4,6-dione
- Step 2 5-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-7-isopropyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-dione
- Step 1 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-8-methoxy-1H-quinazoline-2,4-dione
- Step 2 3-[2-Chloro-4-(2-phenylethynyl)phenyl]-8-methoxy-1-methyl-quinazoline-2,4-dione
- Step 2 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1-(oxetan-3-yl)guinazoline-2,4-dione
- Step 2 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1-isopropyl-pteridine-2,4-dione
- Step 1 Ethyl 5-[(2,6-difluoro-4-iodo-phenyl)carbamoylamino]-3-methyl-imidazole-4-carboxylate
- Step 3 1-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-3,7-dimethyl-purine-2,6-dione
- Step 1 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-8-methoxy-1H-quinazoline-2,4-dione
- Step 2 3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-8-methoxy-1-methyl-quinazoline-2,4-dione
- Step 1 3-[4-Bromo-2-fluoro-6-(trifluoromethyl)phenyl]-1-isopropyl-quinazoline-2,4-dione
- Step 2 3-[2-Fluoro-4-(2-phenylethynyl)-6-(trifluoromethyl)phenyl]-1-isopropyl-quinazoline-2,4-dione
- Step 1 8-(2,2-Difluoroethoxy)-3-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-1H-quinazoine-2,4-dione
- Step 2 8-(2,2-Difluoroethoxy)-3-[2, 6-difluoro-4-(2-phenylethynyl)phenyl]-1-methyl-quinazoline-2,4-dione
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/283,010 US9676732B2 (en) | 2013-09-25 | 2016-09-30 | Ethynyl derivatives |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13185856.5 | 2013-09-25 | ||
EP13185856 | 2013-09-25 | ||
PCT/EP2014/070100 WO2015044075A1 (en) | 2013-09-25 | 2014-09-22 | Ethynyl derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/070100 Continuation WO2015044075A1 (en) | 2013-09-25 | 2014-09-22 | Ethynyl derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/283,010 Continuation US9676732B2 (en) | 2013-09-25 | 2016-09-30 | Ethynyl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160207890A1 true US20160207890A1 (en) | 2016-07-21 |
Family
ID=49230629
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/081,573 Abandoned US20160207890A1 (en) | 2013-09-25 | 2016-03-25 | Ethynyl derivatives |
US15/283,010 Active US9676732B2 (en) | 2013-09-25 | 2016-09-30 | Ethynyl derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/283,010 Active US9676732B2 (en) | 2013-09-25 | 2016-09-30 | Ethynyl derivatives |
Country Status (28)
Country | Link |
---|---|
US (2) | US20160207890A1 (es) |
EP (1) | EP3049409B1 (es) |
JP (1) | JP6134441B2 (es) |
KR (1) | KR101757603B1 (es) |
CN (1) | CN105579447B (es) |
AR (1) | AR097721A1 (es) |
AU (1) | AU2014327504B2 (es) |
BR (1) | BR112016005994A2 (es) |
CA (1) | CA2924376A1 (es) |
CL (1) | CL2016000677A1 (es) |
CR (1) | CR20160075A (es) |
DK (1) | DK3049409T3 (es) |
EA (1) | EA029352B1 (es) |
ES (1) | ES2630319T3 (es) |
HK (1) | HK1220200A1 (es) |
HU (1) | HUE034849T2 (es) |
IL (1) | IL244039B (es) |
MA (1) | MA38885B1 (es) |
MX (1) | MX370341B (es) |
MY (1) | MY183953A (es) |
PE (1) | PE20160666A1 (es) |
PH (1) | PH12016500427A1 (es) |
PL (1) | PL3049409T3 (es) |
SG (1) | SG11201602029VA (es) |
SI (1) | SI3049409T1 (es) |
TW (1) | TWI527801B (es) |
UA (1) | UA116277C2 (es) |
WO (1) | WO2015044075A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034699B2 (en) | 2015-07-15 | 2021-06-15 | Hoffmann-La Roche Inc. | Ethynyl derivatives |
US11242349B2 (en) | 2016-07-18 | 2022-02-08 | Hoffmann-La Roche Inc. | Ethynyl derivatives |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106029649B (zh) * | 2014-02-25 | 2019-02-12 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
JP6539749B2 (ja) * | 2015-03-19 | 2019-07-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | mGluR4のモジュレーターとしての3−(4−エチニルフェニル)ヘキサヒドロピリミジン−2,4−ジオン誘導体 |
AR105556A1 (es) * | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
US10308656B2 (en) | 2015-08-18 | 2019-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of Ku70/80 and uses thereof |
AU2019309448A1 (en) | 2018-07-26 | 2021-01-14 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935907A (en) * | 1997-03-31 | 1999-08-10 | Nihon Bayer Agrochem K.K. | Phenylacetylene derivatives |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
NZ581817A (en) * | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
JP2013503909A (ja) * | 2009-09-04 | 2013-02-04 | ヴァンダービルト ユニバーシティー | mGLuR4アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
KR20120120416A (ko) * | 2010-02-11 | 2012-11-01 | 벤더르빌트 유니버시티 | Mglur4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법 |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
CA2798514A1 (en) * | 2010-05-12 | 2011-11-17 | P. Jeffrey Conn | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
CN102503888A (zh) * | 2011-10-08 | 2012-06-20 | 西安交通大学 | 2-芳基-1,3-异喹啉二酮类抗肿瘤化合物及其合成方法和用途 |
-
2014
- 2014-09-22 PL PL14781474T patent/PL3049409T3/pl unknown
- 2014-09-22 WO PCT/EP2014/070100 patent/WO2015044075A1/en active Application Filing
- 2014-09-22 CA CA2924376A patent/CA2924376A1/en not_active Abandoned
- 2014-09-22 KR KR1020167007447A patent/KR101757603B1/ko active IP Right Grant
- 2014-09-22 EA EA201690408A patent/EA029352B1/ru not_active IP Right Cessation
- 2014-09-22 AU AU2014327504A patent/AU2014327504B2/en not_active Ceased
- 2014-09-22 MA MA38885A patent/MA38885B1/fr unknown
- 2014-09-22 MY MYPI2016000532A patent/MY183953A/en unknown
- 2014-09-22 EP EP14781474.3A patent/EP3049409B1/en active Active
- 2014-09-22 AR ARP140103499A patent/AR097721A1/es unknown
- 2014-09-22 HU HUE14781474A patent/HUE034849T2/en unknown
- 2014-09-22 CN CN201480052343.0A patent/CN105579447B/zh active Active
- 2014-09-22 UA UAA201604513A patent/UA116277C2/uk unknown
- 2014-09-22 PE PE2016000237A patent/PE20160666A1/es active IP Right Grant
- 2014-09-22 SG SG11201602029VA patent/SG11201602029VA/en unknown
- 2014-09-22 MX MX2016002717A patent/MX370341B/es active IP Right Grant
- 2014-09-22 ES ES14781474.3T patent/ES2630319T3/es active Active
- 2014-09-22 JP JP2016517337A patent/JP6134441B2/ja active Active
- 2014-09-22 DK DK14781474.3T patent/DK3049409T3/en active
- 2014-09-22 SI SI201430272T patent/SI3049409T1/sl unknown
- 2014-09-22 BR BR112016005994A patent/BR112016005994A2/pt not_active Application Discontinuation
- 2014-09-23 TW TW103132854A patent/TWI527801B/zh not_active IP Right Cessation
-
2016
- 2016-02-09 IL IL244039A patent/IL244039B/en not_active IP Right Cessation
- 2016-02-16 CR CR20160075A patent/CR20160075A/es unknown
- 2016-03-04 PH PH12016500427A patent/PH12016500427A1/en unknown
- 2016-03-23 CL CL2016000677A patent/CL2016000677A1/es unknown
- 2016-03-25 US US15/081,573 patent/US20160207890A1/en not_active Abandoned
- 2016-07-15 HK HK16108345.7A patent/HK1220200A1/zh unknown
- 2016-09-30 US US15/283,010 patent/US9676732B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935907A (en) * | 1997-03-31 | 1999-08-10 | Nihon Bayer Agrochem K.K. | Phenylacetylene derivatives |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034699B2 (en) | 2015-07-15 | 2021-06-15 | Hoffmann-La Roche Inc. | Ethynyl derivatives |
US11242349B2 (en) | 2016-07-18 | 2022-02-08 | Hoffmann-La Roche Inc. | Ethynyl derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9676732B2 (en) | Ethynyl derivatives | |
US20210269452A1 (en) | Ethynyl derivatives | |
US9695128B2 (en) | Ethynyl derivatives | |
US8586581B2 (en) | Ethynyl compounds useful for treatment of CNS disorders | |
US9725416B2 (en) | Ethynyl derivatives | |
US10065956B2 (en) | Ethynyl derivatives | |
US10011607B2 (en) | Ethynyl derivatives | |
US11345708B2 (en) | Substituted imidazo[1,2-a]imidazoles as modulators of metabotropic glutamate receptor 4 activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |